BEAT vs. IMAC, INO, ANGO, UTMD, OBIO, RCEL, TLSI, DCTH, NPCE, and PROF
Should you be buying BioTelemetry stock or one of its competitors? The main competitors of BioTelemetry include IMAC (IMAC), Inovio Pharmaceuticals (INO), AngioDynamics (ANGO), Utah Medical Products (UTMD), Orchestra BioMed (OBIO), AVITA Medical (RCEL), TriSalus Life Sciences (TLSI), Delcath Systems (DCTH), NeuroPace (NPCE), and Profound Medical (PROF). These companies are all part of the "medical" sector.
BioTelemetry (NASDAQ:BEAT) and IMAC (NASDAQ:IMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
7.8% of BioTelemetry shares are owned by institutional investors. Comparatively, 24.3% of IMAC shares are owned by institutional investors. 20.9% of BioTelemetry shares are owned by insiders. Comparatively, 10.0% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
BioTelemetry currently has a consensus target price of $8.00, indicating a potential upside of 187.77%. Given BioTelemetry's higher possible upside, analysts plainly believe BioTelemetry is more favorable than IMAC.
IMAC has higher revenue and earnings than BioTelemetry.
In the previous week, BioTelemetry had 1 more articles in the media than IMAC. MarketBeat recorded 2 mentions for BioTelemetry and 1 mentions for IMAC. BioTelemetry's average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.
BioTelemetry received 318 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 63.77% of users gave BioTelemetry an outperform vote while only 60.17% of users gave IMAC an outperform vote.
BioTelemetry has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat BioTelemetry's return on equity.
BioTelemetry has a beta of -1.12, suggesting that its stock price is 212% less volatile than the S&P 500. Comparatively, IMAC has a beta of -0.88, suggesting that its stock price is 188% less volatile than the S&P 500.
Summary
BioTelemetry beats IMAC on 7 of the 13 factors compared between the two stocks.
Get BioTelemetry News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BEAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioTelemetry Competitors List
Related Companies and Tools
